AC Immune (NASDAQ:ACIU) Stock Price Down 1.6%

Shares of AC Immune SA (NASDAQ:ACIU) were down 1.6% during mid-day trading on Thursday . The stock traded as low as $3.71 and last traded at $3.81. Approximately 726,441 shares traded hands during mid-day trading, an increase of 174% from the average daily volume of 265,348 shares. The stock had previously closed at $3.87.

Analysts Set New Price Targets

ACIU has been the subject of a number of recent research reports. BTIG Research initiated coverage on shares of AC Immune in a report on Friday, May 31st. They issued a “buy” rating and a $8.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of AC Immune in a research note on Friday, March 15th. Finally, StockNews.com raised AC Immune from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th.

AC Immune Stock Performance

The firm has a market capitalization of $376.81 million, a price-to-earnings ratio of -5.52 and a beta of 1.27. The business’s 50 day moving average is $3.65 and its 200-day moving average is $3.54.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06). Equities research analysts forecast that AC Immune SA will post -0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On AC Immune

Several large investors have recently bought and sold shares of the stock. Lazard Asset Management LLC bought a new stake in shares of AC Immune in the 1st quarter worth approximately $30,000. BNP Paribas Financial Markets raised its position in AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after purchasing an additional 8,423 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in AC Immune during the fourth quarter worth about $48,000. Nixon Peabody Trust Co. bought a new position in AC Immune during the fourth quarter worth about $64,000. Finally, Redmile Group LLC lifted its position in shares of AC Immune by 0.4% during the 1st quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after buying an additional 7,031 shares during the period. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.